Does early anemia correction prevent complications of chronic renal failure?

Clinical Nephrology

Volumn 51, Issue 1, 1999, Pages 1-11

  Drueke T B ^a   Eckardt, K U ^b   Frei, U ^b   Jacobs, C ^c   Kokot, F ^d   McMahon, L P ^e   Schaefer, R M ^f  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b HUMBOLDT UNIVERSITY   (Germany)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d MEDICAL UNIVERSITY OF SILESIA   (Poland)

^e ROYAL MELBOURNE HOSPITAL   (Australia)

^f UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Anemia; Chronic renal failure (CRF); Recombinant human erythropoietin (rhEPO)

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN; HLA ANTIBODY; RECOMBINANT ERYTHROPOIETIN;

AEROBIC CAPACITY; ANEMIA; ANGINA PECTORIS; BLOOD TRANSFUSION; CARDIOVASCULAR EFFECT; CHRONIC KIDNEY FAILURE; COGNITION; DIALYSIS; EMPLOYMENT; HEART LEFT VENTRICLE HYPERTROPHY; HEMOSTASIS; HOSPITAL ADMISSION; HUMAN; MORTALITY; QUALITY OF LIFE; REVIEW; RISK FACTOR; SOCIALIZATION; VIRUS TRANSMISSION; VOCATIONAL REHABILITATION;

ANEMIA; BLOOD TRANSFUSION; ERYTHROPOIETIN, RECOMBINANT; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; RENAL DIALYSIS;

EID: 0344923792     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (121)

1. Abraham PA, Opsahl JA Rachel KM, Asinger R, Halstenson CE 1990 Renal function during erythropoietin therapy for anaemia in predialysis chronic renal failure patients. Am J Nephrol 10: 128-136
2. Albitar S, Meulders Q, Hammoud H, Soutif C, Bouvier P, Pollini J 1995 Subcutaneous versus intravenous administration of erythropoietin improves its efficiency for lhe treatment of anemia in haemodialysis patients. Nephrol Dial Transplant 10 (Suppl 6): 40-43
3. Baczynski R, Massry SG, Magott M, El-Belbessi S, Kohan R, Brautbar N 1985 Effect of parathyroid hormone on energy metabolism of skeletal muscle. Kidney Int 28: 722-727
4. Bakir N. Sluiter WJ, Pleog RJ, Van Son WJ, Tegzess AM 1996 Primary renal graft thrombosis. Nephrol Dial Transplant 74: 687-693
5. Barany P, Wibom R, Hultman E, Bergström J 1991 ATP production in isolated muscle mitochondria from haemodialysis patients: correction of anaemia with erythropoietin. Clin Sci 81: 645-653
6. Besarab A, Bolton K, Browne JK et al 1998 The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis an epoetin. N Engl J Med 339:584-590
7. Bhandari S, Norfolk D, Brownjohn A, Turney J 1997 Evaluation of RBC ferritin and reticulocyte measurements in monitoring response to intravenous iron therapy. Am J Kidney Dis 30: 814-821
8. Briggs WA, Gimenez LF 1994 Clinical application of recombinant human erythropoietin in predialysis renal failure. Hematol Oncol Clin North Am 8: 927-932
9. Buckner FS, Eschbach JW, Haley NR, Davidson RC, Adamson JW 1990 Hypertension following erythropoietin therapy in anemic hemodialysis patients. Am J Hypertens 3: 947-955
10. Campese V 1997 Neurogenic factors and hypertension in chronic renal failure. J Nephrol 10: 184-187
11. Canadian Erythropoietin Study Group 1990 Association between recombinant erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ 300: 573-578
12. Caravaca F, Lopez-Minguez JR, Arrobas M et al 1995 Haemodynamic changes induced by the correction of anemia by erythropoietin: role of antiplatelet therapy. Nephrol Dial Transplant 10: 1720-1724
13. Caravaca F, Pizzaro JL, Arrobas M, Cubero JJ, Garcia MC, Perez-Miranda M 1994 Antiplatelet therapy and development of hypertension induced by recombinant human erythropoietin in uremic patients. Kidney Int 45: 845-851
14. Carlini R, Obialo CI, Rothstein M 1993 Intravenous r-HuEPO administration increases plasma endothelin and blood pressure in hemodialysis. Am J Hypertens 6: 103-107
15. Caro J, Erslev AJ 1995 Anemia of chronic renal failure. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ (eds) Williams' Hematology. 5th edn. McGraw-Hill, New York, 456-462
16. Casati S, Passerini P, Campsie MR et al 1987 Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis. Br Med J 295: 1017-1020
17. Churchill DN, Taylor W. Cook RJ et al 1992 The Canadian hemodialysis morbidity study. Am J Kidney Dis 19: 214-234
18. Clyne N, Ekholm J, Jogestrand T, Lins LE, Pehrsson SK 1991 Fffects of exercise training in predialytic uremic patients. Nephron 59: 84-89
19. Clyne N, Esbjornsson M, Jansson E, Jogestrand T, Lins LE, Pehrsson SK 1993 Effects of renal failure on skeletal muscle. Nephron 63: 395-399
20. Danielson B 1995 R-HuEPO unresponsiveness - who and why? Nephrol Dial Transplant 10 (Suppl 2): 69-73
21. Davenport A, King RF, Ironside JW, Will KJ, Davidson AM 1993 The effect of treatment with recombinant human erythropoietin on the histological appearance and glycogen content of skeletal muscle in patients with chronic renal failure treated by regular hospital hemodialysis. Nephron 64: 89-94
22. Delano BG 1989 Improvements in quality of life following treatment with r-HuEPO in anemic hemodialysis patients. Am J Kidney Dis 14 (Suppl 1): 14-18
23. Desforges JF, Dawson JP 1958 The anemia of renal failure. Arch Intern Med 101: 326
24. Deykin D 1983 Nephrology Forum: uremic bleeding, Kidney Int 24: 698-705
25. Diesel W, Noakes TD, Swanpoel C, Lambert M 1990 Isokinetic muscle strength predicts maximum exercise tolerance in renal patients on chronic hemodialysis. Am J Kidney Dis 16: 109-114
26. Drüeke T, Zins B, Naret C et al 1989 Utilization of erythropoietin in the treatment of the anemia due to chronic renal failure. Adv Nephrol Necker Hosp 18: 187-206
27. Eckardt K-U 1994 Erythropoietin. Oxygen dependent control of erythropoiesis and its failure in renal disease. Nephron 67: 7-23
28. Eckardt K-U, Pugh CW, Meier M, Tan CC, Ratcliffe PJ, Kurtz A 1994 Production of erythropoietin by liver cells in vivo and in vitro. Ann NY Acad Sci 718: 50-60
29. Eschbach JW 1995 The future of r-HuEPO. Nephrol Dial Transplant 10 (Suppl 2): 96-109
30. Eschbach JW, Adamson JW 1991 Hematologie consequences of renal failure. In: Brenner BM, Rector FC: The Kidney. 4th ed. Saunders, Philadelphia, 2019
31. Eschbrach JW, Cook JD, Scribner BH, Finch CA 1977 Iron balance in hemodialysis patients. Ann Intern Med 87: 710-713
32. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW 1987 Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. N Engl J Med 316: 73-78
33. Eschbach JW, Glenny R, Robertson T et al 1993 Normalizing the hematocrit (HCT) in hemodialysis patients with EPO improves quality of life and is safe. J Am Soc Nephrol 4: 425
34. Foley RN, Parfrey PS, Harnett JD et al 1995 Clinical and echocardiographic cardiovascular disease in patients starting end-stage renal disease therapy: prevalence, associations and prognosis. Kidney Int 47: 186-192
35. Foley RN, Parfrey S. Harnett JD, Kent GM, Marray JC, Barre BE 1995 The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol 5: 2024-2031
36. Frei U, Nonnast-Duniel B, Schaffer J, Koch KM 1990 Adverse cardiovascular effects of partial correction of renal anemia by recombinant human erythropoietin. Contrib Nephrol 82: 72-78
37. Frenken LAM, Verberckmoes R, Michelsen P, Koene RAP 1989 Efficacy and tolerance of treatment with recombinant human erythropoietin in chronic renal failure (pre-dialysis) patients. Nephrol Dial Transplant 4: 782-786
38. Friedlaender MM, Azem O, Rubinger D, Brautbar C 1996 Effect of human recombinant erythropoletin therapy on panel reactive antibodies in chronic dialysis patients. Isr J Med Sci 32: 730-736
39. Garcia DL Anderson S, Rennke HG, Brenner BM 1988 Anemia lessens and its prevention with recombinant human erythropoietin worsens glomerular injury and hypertension in rats with reduced renal mass. Proc Natl Acad Sci USA 85: 6142-6146
40. Gleiter CH 1996 Posttransplant erythrocytosis: a model for the investigation of the pharmacological control of renal erythropoietin production? Int J Pharmacol Trer 34: 489-492
41. Gimenez LF, Scheel PJ 1994 Clinical application of recombinant erythropoietin in renal dialysis patients. Haematol/Oncol Clin North Am 8: 913-926
42. Goch J, Birgegard G. Danielson BG, Wikstrom K 1996 Iron absorption in patients with chronic uremia on maintenance hemodialysis and in healthy volunteers measured with a simple oral iron loading fest. Nephron 73: 403-406
43. Gogusev J. Zhu D-L, Hémbert T, Ammarguellat F, Marche P, Drücke T 1994 Effect of erythropoietin on DNA synthesis, proto-oncogene expression and phospholipase C activity in rat vascular smooth muscle cells. Biochem Biophys Res Commun 199: 977-983
44. Gretz N, Lasserre JJ, Meisenger E et al 1987 Potential side-effects of erythropoietin. Lancet (Letter) 1: 46
45. Grimm PC, Sinai Trierman L. Sekiya NM et al 1990 Effects of recombinant human enthropoletin on HLA sensitization and cell-mediated immunity. Kidney Int 38: 12-18
46. Guthrie M. Cardenas D, Eschbach JW, Haley NR, Robertson HT, Evans RW 1993 Effects of erythropoietin on strength and functional status of patients on hemodialysis. Clin Nephrol 39: 97-102
47. Harnett JD, Kent GM, Foley RN, Parfrey RS 1995 Cardiac function and hematocrit level. Am J Kidney Dis 25 (Suppl 1): 53-57
48. Heidenrich S, Ralin K-H, Zidek W 1991 Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels. Kidney Int 39: 259-265
49. Heidenreich S, Tepel M. Fahrenkamp A. Rahn KH 1995 Prognostic value of serum erythropoietin levels in late acute rejection of renal transplants. Am J Kid Dis 25: 775-780
50. Hocken AG, Marwah PK 1971 latrogenic contribution to anemia in chronic renal failure. Lancet I: 164-165
51. Ifudu O, Friedman EA 1996 The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. New Engl J Med 334: 420-425
52. Jones AL, Millar JI. 1989 Growth factors in haemopoiesis. Baillieres Clin Haematol 2: 83-111
53. Joske RA, McAlister JM, Prankerd TAJ 1956 Isotope investigations of red cell production and destruction in chronic renal disease. Clin Sci 15: 511
54. Jensen JD, Hansen HE, Pedersen EB 1994 Increased serum erythropoietin level during azathioprine treatment in renal transplant recipients. Nephron 67: 297-301
55. Kalantar-Zadeh K, Hoffken B, Wunsch H, Fink H, Kleiner M, Luft FC 1995 Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era. Am J Kidney Dis 26: 292-299
56. Kamata K, Marunto F, Onoyama K 1991 Hemodynamic mechanism of the elevation in blood pressure following the improvement of anemia with recombinant human erythropoietin. Japan Circul J 55: 649-656
57. Katoa A, Hishida A, Kumagi H, Furuya R, Nakajima T, Honda N 1994 Erythropoietin production in patients with chronic renal failure. Ren Fail 16: 645-651
58. Kaufman JS, Reda DJ, Fye CL et al 1998 Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. N Engl J Med 339:578-583
59. Kessler M 1995 Erythropoietin and erythropoiesis in renal transplantation. Nephrol Dial Transplant 19 (Suppl 6): 114-116
60. Kettner-Melsheimer A, Weiss M, Huber W 1987 Physical work capacity in chronic renal disease. Int J Artif Organs 10: 23-30
61. Kleinman KS, Schweitzer SU, Perdue ST, Bleifer KH, Abels RI 1989 The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: a double-blind, placebo-controlled trialt Am J Kidney Dis 14: 486-495
62. Koch KM, Koene RAP, Messinger D, Quarder O, Scigalla P 1995 The use of epoetin beta in anemic predialysis patients with chronic renal failure. Clin Nephrol 3: 201-208
63. Koene RAP, Frenken LAM 1992 Role of r-HuEPO in treatment of uremic anemia prior to endstage renal disease. Kidney Int 42 (Suppl 38): S142-S147
64. Koch KM, Patyana WD, Shaldon S, Werner E 1974 Anemia of the regular hemodialysis patient and its treatment. Nephron 12: 405-419
65. Kojima K, Totsuka Y 1995 Anemia due to reduced serum erythropoielin concentration in nonuremic diabetic patients. Diabetes Res Clin Pract 27: 229-233
66. Kokot K, Wiecek A 1989 Endocrine changes in chronic dialysis patients. In: Maher JF (ed): Replacement of renal function by dialysis. 3rd ed. Kluwer, Dordrecht
67. Kokot F, Wiecek A, Mesjsuz J, Adam Czak M, Speichowicz U 1997 Influence of rHuEpo therapy on plasma leptin concentration in haemodialysed uraemic patients. Nephrol Dial Transplant (Abstract) 12: A194
68. Kokot F, Wiecek A, Mesjsuz J, Adam Czak M, Speichowicz U 1998 Influence of long-term recombinant human erythropoietin (rHuEpo) therapy on plasma leptin and neuropeptide Y concentration in haemodialysed uraemic patients. Nephrol Dial Transplant 13: 1200-1205
69. Kokot F, Wiecek W, Schmidt-Gayk H et al 1995 Function of endocrine organs in hemodialyzed patients of long-term erythropoietin therapy. Artif Organs 19: 428-435
70. Kooistra MP, van Es A, Strayvenberg A, Marx JJ 1991 Iron metabolism in patients with the anemia of end-stage renal disease during treatment with recombinant human erythropoietin. Br J Haematol 79: 634-639
71. Kooistra MP, Niemansverdreit EC, van Es A, Mol-Beermann NM, Struyvenberg A, Marx JJ 1998 Iron absorption in erythropoietin-treated haemodialysis patients: effects of iron availability, inflammation and aluminium. Nephrol Dial Transplant 13: 2-8
72. Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O 1997 Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 77: 176-185
73. Lewis KJ, Hunsicker LG. Bain RP, Rohde RD, for the Collaborative Study Group 1993 The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329: 1456-1562
74. Lim VS, DeGowin RL, Zavala D, Kircher PT, Abels R, Perry P, Fangman J 1989 Recombinant human erythropoietin treatment in pre-dialysis patients. A double-blind placebo-controlled trial. Ann Intern Med 110: 108-111
75. Linton AL, Clark WF, Driedger AA, Werb R, Lindsay RM 1977 Correctable factors contributing to the anemia of dialysis patients. Nephron 19: 958
76. Loge JP, Lange RD, Moore CV 1958 Characterization of the anemia associated with chronic renal insufficiency. Am J Med 1958, 4-18
77. London GM, Zins B Pannier B et al 1989 Vascular changes in hemodialysis patients in response to recombinant human erythropoietin. Kidney Int 36: 878-882
78. Low-Friedrich I. Grützmacher P, Marz W, Bergmann M, Schoeppe W 1990 Long-term echocardiographic examinations in chronic hemodialysis patients substituted with recombinant human erythropoietin. Blood Purif 8: 272-278
79. Martino R, Oliver A, Ballarin JM, Remacha AF 1994 Postrenal transplant erythrocytosis: further evidence implicating erythropoietin production by the native kidneys. Ann Hematol 68: 201-203
80. Mason K, McMahon LP 1997 Normalization of haemoglobin in haemodialysis patients: a comparative study. Nephrology 3 (Suppl I): S305
81. Maxwell PH, Fergusson DJP, Osmond MK et al 1994 Expression of a homologously recombined erythropoietin-SV 40 Tantigen fusion gene in mouse liver: evidence for erythropoietin production by Ito cells. Blood 84: 1823-1830
82. Mitchell TR, Pegrum GD 1971 The oxygen affinity of haemoglobin in chronic renal failure. BrJ Haematol 21: 463-472
83. Milman N, Larsen L 1975 Iron absorption in patients with chronic renal failure not requiring dialytic therapy. Acta Med Scand 198: 511-517
84. Mitch WE 1998 Robert H Herman Memorial Award in Clinical Nutrition Lecture, 1997. Mechanisms causing loss of lean body mass in kidney disease. Am J Clin Nutr 67: 359-366
85. Muirhead N. Bargman J. Burgess E et al 1995 Evidence-based recommendations for the clinical use of recombinant human erythropoietin. Am J Kidney Dis 26 (Suppl 1): S1-S24
86. Muirhead N, Cattran DC, Zaltman J et al 1994 Safety and efficacy of recersbinant human erythropoietin in correcting the anemia of patients with chronic renal allograft dysfunction. J Am Soc Nephrol 5: 1216-1222
87. Nankivell BJ, Allen RD, O'Connell PJ, Chapman JR 1995 Erythrocytosis after renal transplantation: risk factors and relationship with GFR. Clin Transplant 9: 375-382
88. Nishizawa Y, Shoji T, Tanaka S, Yamashita M, Marita A, Emoto M, Tabata T, Inoue T, Morii H 1998 Plasma leptin level and its relationship with body composition in hemodialysis patients. Am J Kidney Dis 31: 655-661
89. Nissenson AR 1989 Recombinant human erythropoietin: impact on brain and cognitive function, exercise tolerance, sexual potency, and quality of life. Semin Nephrol 9 (Suppl 2): 25-31
90. Nonnast-Daniel B. Deschodt G, Brunkhorst R, Creutzig A, Bahlmann J, Shaldon S, Koch KM 1990 Long-term effects of treatment with recombinant human erythropoletin on haemodynamics and tissue oxygenation in patients with renal anemia. Nephrol Dial Transplant 5: 444-448
91. Onoyama K, Kumagi H, Takeda K, Shimamatsu K, Fujishima M 1989 Effects of recombinant human erythropoietin on anemia, systemic haemodynamics and renal function in predialysis renal failure patients. Nephrol Dial Transplant 4: 966-970
92. Portoles J, Torralbo A, Martin P, Rodrigo J, Herrero JA, Barrientos A 1997 Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 29: 541-548
93. Qureshi AR, Alvestrand A, Danielsson A, Divino-Filbo JC, Gutierrez A, Lindholm B, Hernström J 1998 Factors predicting malnutrition in hemodialysis patients: a cross-sectional study. Kidney Int 53: 773-782
94. Rault R, Magone M 1996 The effect of parathyroidectomy on hematocrit and erythropoietin dose in patients on hemodialysis. ASAIO J 42: M901-M903
95. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M 1993 Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 118: 577-581
96. Rao SD, Shih M-S, Mohini R 1993 Effect of serum parathyroid hormone and bone marrow fibrosis on the response to eryrthropoietin in anemia. N Engl J Med 328: 171-175
97. Robertson HT, Haley NR, Guthrie M, Cardenas D, Eschbach JW, Adamson JW 1990 Recombinant erythropoietin improves exercise capacity in anemic hemodialysis patients. Am J Kidney Dis 15: 325-332
98. Rosenmund A, Binswanger U, Straub PW 1975 Oxidative injury to erythrocytes, cell rigidity, and splenic hemolysis in hemodialyzed urernic patients. Ann Intern Med 82: 460-465
99. Roth D, Smith RD, Schulman TI et al 1994 Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. Am J Kidney Dis 24: 777-784
100. Samtleben W. Baldamus CA, Bommer J et al 1988 Blood pressure changes during treatment with rccombinant human erythropoietin. Contrib Nephrol 66: 114-122
101. +. pH and different haemoglobin levels on maximal exercise performance in haemodialysis patients. Nephrology 3 (Suppl I): S304-S305
102. Sangkabutra T, McKenna MJ, Mason K, Crankshaw DP, McMahon LP 1997 Impaired potassium regulation may contribute to reduced maximal exercise performance in haemodialysis patients (HDP). Nephrology 3 (Suppl 1): S305
103. Saragoca MA, Canziani ME, Cassiolato JL, Gil MA, Andrade JL, Draibe SA, Martinez EE 1991 Left ventricular hypertrophy as a risk factor for arrhythmias in hemodialysis patients. J Cardiovasc Pharmacol 17 (Suppl 2): S136-S138
104. Schaefer RM, Leschke M, Strauer BE, Heidland A 1988 Blood rheology and hypertension in hemodialysis patients treated with erythropoietin. Am J Nephrol 8: 449-453
105. Schmidt R, Kupin W, Dumler F, Venkat KK, Mozes M 1993 Influence of the pretransplant hematocrit level on early graft function in primary cadaveric renal transplantation. Transplantation 55: 1034-1040
106. Schoenmakere De G, Lameire N, Dhondt et al 1998 The haematopoietic effect of recombinant human erythropoietin in haemodialysis patients is independent of the mode of administration (i.v. or s.c.) Nephrol Dial Transplant 13: 1770-1775
107. Shaw B 1967 Hemolysis in chronic renal failure. BMJ 2: 213-216
108. Sheingold SH, Churchill DN, Muirhead N, Laupicas A 1991 Recombinant human erythropoietin. Factors to consider in cost benefit analysis. Am J Kidney Dis 17: 86-92
109. Stenvinkel P 1998 Leptin - a new hormone of definite interest for the nephrologist. Nephrol Dial Transplant (Editorial) 13: 1099-1101
110. Sunder-Plussman G, Hörl W 1995 Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant 10:2070-2076
111. Tarng D-C, Huang J-P, Doong T-I 1998 Improvement of nutritional status in patients receiving maintenance hemodialysis after correction of renal anemia with recombinant human erythropoietin. Nephron 78: 253-259
112. Teruel JL, Aguilera A. Marcen R, Navarro Antolin J, Garcia Otero G, Ortuno J 1996 Androgen therapy for anemia of chronic renal failure. Indications in the erythropoietin era. Scand J Urol Nephrol 30: 403-408
113. Torralbo A, Herrero JA, Portoles J, Fontanellas A, Barrientos A 1995 Activation of the sympathetic nervous system in hemodialysed patients treated with EPO. Nephron 69: 350
114. Touam M, Perez Oliva J, Zingraff J, Drüeke T 1994 Does intravenous erythropoietin lead to an immediate. transient rise in arterial blood pressure in dialysis patients? Nephron (Letter) 67: 240-241
115. Tucker B, Fabbian F, Giles M, Thuaisingham RC, Raine AE, Baker LR 1997 Left ventricular hypertrophy and ambulatory blood pressure monitoring in chronic renal failure. Nephrol Dial Transplant 12: 724-728
116. Van Loo, Vanholder R, Bernaert P, De Roose J, Lameire N 1996 Recombinant human erythropoietin corrects anaemia during the first weeks after renal transplantation: a randomised prospective study. Nephrol Dial Transplant 11: 1815-1821
117. Vasquez EM, Pollak R 1996 Effect of pretransplant erythropoietin on renal allograft outcome. Transplantation 62: 1026-1028
118. Williams B, Hattersley J, Layward E, Walls J 1991 Metabolic acidosis and skeletal muscle adaptation to low protein diets in chronic uremia. Kidney Int 40: 779-786
119. Winearls CG 1995 Historical review on the use of recombinant human erythropoietin in chronic renal failure. Nephrol Dial Transplant 10 (Suppl 2): 3-9
120. Wolcott DL, Marsh JT, La Rue A, Carr C. Nissenson AR 1989 Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients. Am J Kidney Dis 14: 478-485
121. Zachee P 1995 Controversies in selection of epoetin dosages. Issues and answers. Drugs 49: 536-547